CLINICAL_TRIALS
trial_result
· 2020-08-13
Clinical Trial Update: UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia [Phase 1]
Summary
Phase 1 clinical trial of UC-961 (cirmtuzumab) in relapsed or refractory chronic lymphocytic leukemia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Thomas Kipps | Conditions: Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2020-08-13